La catena delle opzioni mostra i dati chiave delle opzioni azionarie di NewRiver REIT a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per NewRiver REIT..

NewRiver REIT (OTC:NRWRF) Azioni, Catena delle Opzioni

NewRiver REIT PLC is a real estate investment trust that invests in, manages, and develops retail and leisure properties. The company's property portfolio comprises shopping centers, retail warehouses, and pubs across the United Kingdom. The retail properties contribute a substantial amount to the total revenue, and these are largely located in Yorkshire and Humberside, London, Northeast and Southeast England, Scotland, and Wales. The company generates a majority of its revenue from leasing properties to tenants, which include discount retailers, fashion and accessory stores, groceries, homeware and furniture stores, and dining venues among others.

NEWRIVER REIT PLC REIT by Newriver Reit Plc

NewRiver REIT PLC

News

Contracts

KOPN

Kopin Announces That Startup Get Your Way Selected Co.'s Golden Pearl Optical Module For Its aRdent 2 Assisted Reality Solution

Says Medical Insurance Probe Is "Historic", In Past, Not Involving Any Current Executives; Medical Insurance Probe Began Three Years Ago, Initially Involved Small Number Of Employees; Now 100 Former Employees Have Been Sentenced To Jail Time
-Investor Call

AstraZeneca Says Arrests Of Current And Former Staff Mentioned By CEO In September To Bloomberg Are A Third Issue, Unrelated To Medical Insurance And Wang Investigations; Sought To Quell Concerns About China Business After Report Of Broader Probe Into Potential Insurance Fraud; China Exec. Leon Wang Is Detained By Chinese Authorities As Part Of The Investigation; To The Company's Knowledge; Medical Insurance Probe Reported By Yicai Is Separate From The Leon Wang Investigation

Guidance

Pinnacle West Capital  Estimates 2025 EPS Of $4.40 - $4.60 On Weather-normalized Basis, Est $4.78

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.
In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies. Mukunda also provides updates on IGC Pharma's lead candidate, IGC-AD1, which is currently in Phase 2 trials for treating agitation in Alzheimer's dementia and is progressing toward additional trials to explore its potential as a disease-modifying treatment.
The interview underscores IGC's approach to leveraging artificial intelligence to diversify its pipeline, targeting both neurodegenerative and metabolic disorders to maximize patient impact.
To read the full interview, please visit: <a href="https://pr.report/41tx">Expanding Our Portfolio: IGC Pharma's Strategic Growth in Alzheimer's and Weight Loss Therapies</a>

Biotech

General

IGC Pharma Announces Publication Of IMS Spotlight Interview With CEO Ram Mukunda Highlighting Strategic Expansion In Alzheimer's And Weight Loss Therapies

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

RPRX

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

WIIM

Broadridge Financial Solutions shares are trading higher after Morgan Stanley raised its price target on the stock from $200 to $207.

Keybanc analyst Eric Gonzalez maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Overweight and lowers the price target from $80 to $78.

Keybanc Maintains Overweight on Restaurant Brands Intl, Lowers Price Target to $78

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d94a96b85e930001fd9dd4/kevin-dede">HC Wainwright &amp; Co. analyst Kevin Dede</a> initiated coverage on BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) with a Buy rating and announced a price target of $7. BitFuFu shares closed at $4.57 on Tuesday. <a href="https://www.benzinga.com/quote/FUFU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz initiated coverage on Ryman Hospitality Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Buy rating and announced a price target of $130. Ryman Hospitality shares closed at $108.30 on Tuesday. <a href="https://www.benzinga.com/quote/RHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61826cd080db050001bbb18a/jiong-shao">Barclays analyst Jiong Shao</a> initiated coverage on Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) with an Overweight rating and announced a price target of $19. Vipshop shares closed at $14.58 on Tuesday. <a href="https://www.benzinga.com/quote/VIPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Gary Mobley initiated coverage on Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with an Overweight rating and announced a price target of $62. Rambus shares closed at $50.26 on Tuesday. <a href="https://www.benzinga.com/quote/RMBS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Lee Hambright initiated coverage on Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with an Outperform rating and announced a price target of $300. Insulet shares closed at $241.32 on Tuesday. <a href="https://www.benzinga.com/quote/PODD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PODD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png" alt="" class="wp-image-632774" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51.png 1178w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Initiation

FUFU

PODD

RMBS

VIPS

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

LQR House Inc. (the "Company" or "LQR House") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQR#NASDAQ">LQR</a>), a niche e-commerce platform specializing in the spirits and beverage industry,is thrilled to announce a new marketing collaboration with The New York Cocktail Co., including a launch of a custom campaign highlighting their award-winning ready-to-drink cocktail Negroni, crafted by their team of New York's bartenders. This campaign will focus on driving traffic and sales for their bottled Negroni cocktail on <a href="https://pr.report/41m0">CWSpirits.com</a>.
According to The New York Cocktail Co., their Negroni is more than just a cocktail; it offers convenience without compromising quality, capturing the essence of the bartender-guest connection in every pour. It stands as a tribute to Dante NYC-an iconic Greenwich Village café and a landmark in New York's cocktail scene since 1915. Renato Tonelli, an Italian-American Beverage Director at Dante and the 2023 U.S. Bartender of the Year, has brought his expertise to create this spirited, herbaceous, and impeccably balanced Negroni, now bottled for The New York Cocktail Co.

LQR House Announces Marketing Partnership With The New York Cocktail Co. To Drive Awareness And Sales Of Their Negroni Cocktail On CWSpirits.com

Pinnacle West Capital Adjusts 2024 EPS Guidance Upward From $4.60 - $4.80 To  $5.00 - $5.20, Est $4.85

Tencent Music shares are trading lower. Barclays initiated coverage on the stock and announced a price target of $16.

Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) ("Nuvini"), a leading B2B SaaS acquirer in Latin America, is pleased to announce the successful close of its latest financing round, consisting of a combination of equity and convertible notes. The financing, led by Nuvini's Founder and CEO, Pierre Schurmann, and existing investors, underscores the company's strategic growth vision.
The convertible notes were secured at a conversion price of $1.10 per share. The premium pricing signals not only the company's founder and investors' belief in the company's resilience and growth potential but also a shared commitment to building a robust foundation for sustainable, long-term expansion.
In addition to this strategic financing milestone, Nuvini is pleased to announce the promotion of Mr José Mario Ribeiro to the role of Chief Operating Officer. Since the announcement of Jose Mario as Board Advisor in August, he has made significant contributions to the company, and his transition to this expanded role will enable Nuvini to accelerate its focus on embedding finance within its portfolio companies, further amplifying operational efficiencies and growth opportunities.

Management

NVNI

Nuvini Appoints José Mario Ribeiro As New Chief Operating Officer

REBN

Reborn Coffee Announced It Has Closed Its Acquisition Of A 58% Stake In South Korean Bbang Ssaem Bakery; Terms Not Disclosed

Jones Lang LaSalle shares are trading higher after the company reported better-than-expected Q3 financial results.

The Company's innovative alcohol-reducing beverage, Sure Shot, will be available in 450+ stores across the Chicago area.
JUPITER, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced a new distribution agreement with Huckster, Inc., a leading Direct-to-Store (DSD) distributor in Illinois, to expand the availability of its innovative alcohol-reducing beverage, Sure Shot, in the metro Chicago market.
Sure Shot, the first beverage of its kind, is specifically formulated to reduce blood alcohol content while enhancing mental clarity. Its unique blend of essential B vitamins, antioxidants, electrolytes, and nootropics supports the body's natural metabolic processes to efficiently process alcohol, reducing blood alcohol content (BAC) in as little as 30 minutes. This innovative approach, backed by a recently awarded patent and positive clinical study results, positions Sure Shot as the ideal choice for health-conscious individuals who enjoy an active social life.

SHOT

Safety Shot Expands Reach In Metro Chicago With New Distribution Agreement With Huckster, Inc.

Keybanc analyst Steve Barger downgrades Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) from Overweight to Sector Weight.

Downgrades

Keybanc Downgrades Myers Indus to Sector Weight

EFSH

1847 Holdings Signs Definitive Agreement To Acquire A Cabinet, Door & Millwork Manufacturer For $18.75M

SMCI

Super Micro Computer shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and cut its price target on the stock from $50 to $23.

Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) reported quarterly earnings of $3.37 per share which missed the analyst consensus estimate of $3.48 by 3.16 percent. This is a 3.71 percent decrease over earnings of $3.50 per share from the same period last year. The company reported quarterly sales of $1.77 billion which missed the analyst consensus estimate of $1.87 billion by 5.65 percent. This is a 7.94 percent increase over sales of $1.64 billion the same period last year.

Earnings

Earnings Misses

Pinnacle West Capital Q3 2024 GAAP EPS $3.37 Misses $3.48 Estimate, Sales $1.77B Miss $1.87B Estimate

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)
IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet's FHAB platform which Sonnet believes could&nbsp;present an important oncology possibility
The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic biologics target to IL-18 generating multiple novel cancer drugs
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,134,635 entitled "Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same," covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant). The patent carries a term effective until June 2044.

SONN

Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates; Both Novel Bifunctional And Monofunctional Fusion Proteins Exhibit Wild-Type Binding To The IL-18 Receptor, Coupled With Undetectable Binding To The Inhibitory IL-18 Binding Protein

Comments

NewRiver REIT

NewRiver REIT (NRWRF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO